Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Alpelisib Challenge Test (ACT) for Assessment of Pancreatic β-Cell Reserve
NCT07778524Phase 1Recruiting
- Sponsor
- Columbia University
- Start
- Sep 2026
- Primary completion
- Aug 2028
- Countries
- 1
01
Overview
Phase 1, open-label trial of alpelisib (3 arms), sponsored by Columbia University. Primary endpoint: Correlation coefficient between clamp and ACT/MMTT up to 17 hours. Started Sep 2026; status: recruiting.
02
Drugs
alpelisib
Beyond the preview
Go deeper on NCT07778524.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07778524.